ArticleJournal of clinical immunology2016
Treatment of CGD-associated Colitis with the IL-23 Blocker Ustekinumab.
Article in Journal of clinical immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial.Journal of human immunity · 2026Article
- How I Treat: Chronic granulomatous disease.Journal of human immunity · 2026Review
- Functional neutrophil disorders: Chronic granulomatous disease and beyond.Immunological reviews · 2024Review
- What can inherited immunodeficiencies reveal about pyoderma gangrenosum?Experimental dermatology · 2024Review
- Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease.The Journal of allergy and clinical immunology · 2023Observational
- Linking Genetic Diagnosis to Therapeutic Approach in Very Early Onset Inflammatory Bowel Disease: Pharmacologic Considerations.Paediatric drugs · 2022Review
- Chronic Granulomatous Disease With Inflammatory Bowel Disease: Clinical Presentation, Treatment, and Outcomes From the USIDNET Registry.The journal of allergy and clinical immunology. In practice · 2022Article
- Disease Presentation, Treatment Options, and Outcomes for Myeloid Immunodeficiencies.Current allergy and asthma reports · 2021Review
- Article
- Variable Presentation of the CYBB Mutation in One Family, Approach to Management, and a Review of the Literature.Case reports in medicine · 2020Article
- Geographic Variability and Pathogen-Specific Considerations in the Diagnosis and Management of Chronic Granulomatous Disease.Pediatric health, medicine and therapeutics · 2020Review
- Cellular Therapies in Chronic Granulomatous Disease.Frontiers in pediatrics · 2020Review
- Chronic Granulomatous Disorder-Associated Colitis Can Be Accurately Evaluated with MRI Scans and Fecal Calprotectin Level.Journal of clinical immunology · 2019Article
- The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies.Journal of clinical immunology · 2018Review
- Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature.Gastroenterology research · 2018Review
- Recent advances in understanding and treating chronic granulomatous disease.F1000Research · 2017Review
- Primary Immunodeficiency Diseases: Current and Emerging Therapeutics.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.